ABCC7 p.Lys536Gln

[switch to full view]
Comments [show]
Publications
PMID: 20551307 [PubMed] Da Paula AC et al: "Folding and rescue of a cystic fibrosis transmembrane conductance regulator trafficking mutant identified using human-murine chimeric proteins."
No. Sentence Comment
124 Thus, we identified six residues in 12b-NBD1 (E527Q, E528Q, S531T, K536Q, I539T, and K584E) and 12 residues in 114c-NBD2 (T1263I, P1290T, K1302Q, Y1307N, Q1309K, S1311K, R1325K, V1338T, C1344Y, L1367I, D1394G, and E1409D) (see supplemental Fig. 1 and supplemental Table 1, A and B).
X
ABCC7 p.Lys536Gln 20551307:124:67
status: NEW
Login to comment

150 For example, compare the data for S531T and K536Q in Fig. 2, C and D. Taken together and consistent with the WB data (Fig. 2, A and B, and Table 1), our iodide efflux data suggest that most of the NBD1 and NBD2 mutants exhibited channel activity, arguing that they reach the cell surface.
X
ABCC7 p.Lys536Gln 20551307:150:44
status: NEW
Login to comment

187 TABLE 1 Summary information of CFTR point mutants analyzed in present study CFTR variants Clinical dataa Band C/band Bb (؎S.E., n ‫؍‬ 5) Processingc Normalized processingd Normalized iodide efflux functione (؎S.E., n ‫؍‬ 6) Iodide efflux to processed proteinf % % % % peak intensity % WT-CFTR -g 83 Ϯ 3 77 100 100 Ϯ 8 - Murine - 86 Ϯ 5 66 86 74 Ϯ 4 86 Ϯ 4 E527Q Mild CF 64 Ϯ 5 49 63 46 Ϯ 4 73 Ϯ 4 E528Q - 86 Ϯ 5 79 102 135 Ϯ 16 132 Ϯ 10 S531T - 87 Ϯ 6 81 105 71 Ϯ 5 67 Ϯ 5 K536Q - 69 Ϯ 3 42 54 51 Ϯ 4 94 Ϯ 3 I539T Revertant 112 Ϯ 5 81 105 49 Ϯ 6 46 Ϯ 5 L581F - 118 Ϯ 3 83 107 72 Ϯ 5 67 Ϯ 3 L581F/K584E - 125 Ϯ 2 77 100 100 Ϯ 12 100 Ϯ 8 T1263I Mild CF 75 Ϯ 3 76 98 31 Ϯ 8 31 Ϯ 5 P1290T Asymptomatic 87 Ϯ 3 82 106 92 Ϯ 10 86 Ϯ 6 K1302Q - 72 Ϯ 3 77 100 37 Ϯ 2 37 Ϯ 2 Y1307N - 82 Ϯ 2 76 98 70 Ϯ 5 71 Ϯ 3 Q1309K - 79 Ϯ 4 77 100 26 Ϯ 2 26 Ϯ 3 S1311K - 73 Ϯ 4 72 93 33 Ϯ 7 35 Ϯ 5 R1325K - 64 Ϯ 6 78 101 47 Ϯ 2 46 Ϯ 4 V1338T - 88 Ϯ 2 77 100 37 Ϯ 11 37 Ϯ 6 C1344Y - 71 Ϯ 4 76 98 86 Ϯ 4 87 Ϯ 4 L1367I - 72 Ϯ 5 80 103 36 Ϯ 5 34 Ϯ 5 D1394G - 78 Ϯ 4 86 111 93 Ϯ 12 83 Ϯ 8 E1409D - 70 Ϯ 3 70 90 43 Ϯ 5 47 Ϯ 4 a Data from the CFTR mutation database.
X
ABCC7 p.Lys536Gln 20551307:187:609
status: NEW
Login to comment

PMID: 7914197 [PubMed] Hoof T et al: "Cystic fibrosis-type mutational analysis in the ATP-binding cassette transporter signature of human P-glycoprotein MDR1."
No. Sentence Comment
26 20575 CF-type Mutations in MDRl TABLEI Oligonucleotides used in RTIPCR assays, mutagenesis,and sequencing Sequence Primer' Applicationb 5'-GAGGTGAAGAAGGGCCAGACG-3' mdrlP3175s* P 5'-TTCTGGATGGTGGACAGGCGGTGA-3' mdrlP3716a*P 5'-GTGCAGAGTGGGCAGACGGTG-3' mdrl-1249s 5'-TTACGAACTGTAGACAAACGATGAG-3' 5'-GAGGAGCAGCTTATG-3' 5'-GTGGTTCAGGTGGCT-3' mdrl-1702s S 5'-GAAAACATTCGCTATGGCCGTGAAAATG-3' mdrl-1456s S 5'-GCAGCTGATGAATCC-3' mdrl-1918s S 5"GTGGTGGGCAGgaCAGAGGATCGC-3' mdrl-1595sM (K536Q) 5'-GTTGAGTGGTGuCAGAAGCAGAG-3' mdrl-1590sM (G534D) 5'-GTGGTGGGCAGwCAGAGGATCGC-3' mdrl-1595sM (K536R) 5"CCAGTTGAGGGGTGGGCAG-3' mdrl-1587sM(S532R) 5'-GAAAACATTCGsGCCGTGAAAATG-3' mdrl-1486sM (AY490) 5'-GGCAAGGGCATCCTGGCTGCAGA-3' alh79s* P 5'-TAACGGGCCAGAACATTGGCATT-3' alh521a* P p, s p, s S mdrl-1781a mdrl-1076s The number indicates the positionof the first primer nucleotide in thecorresponding EMBL file cDNA sequences of rabbit aldolase A (ald), human MDRl (mdrl),or CHOMDRl (mdrlc);s, sense direction; a, antisense direction tocDNA sequence.
X
ABCC7 p.Lys536Gln 7914197:26:478
status: NEW
Login to comment

90 The localization ofAY490, S532R, G534D, K536R, K536Q, and AY490-K536Q in the N-terminal half of MDRl is shown in Fig. 1.
X
ABCC7 p.Lys536Gln 7914197:90:47
status: NEW
X
ABCC7 p.Lys536Gln 7914197:90:64
status: NEW
Login to comment

44 The double mutant AY490-K536Q was constructed by digestion of the pBSmdrl single mutants AY490 and K536Q with ApaI and religationof mutated fragments.
X
ABCC7 p.Lys536Gln 7914197:44:24
status: NEW
X
ABCC7 p.Lys536Gln 7914197:44:99
status: NEW
Login to comment

97 All G418-preselected clones grew in the presence of the lowest concentrations of 50 ng of adriamycidml or 100 ng of colchicine/ml (Fig. 21, but only the introduction of wild-type MDRl, K536Q MDRl, or K536R MDRl intoCHO K1 recipients hadconferred resistance toboth drugs above the base-line level of the antisense MDRl transfection control (Fig. 2).
X
ABCC7 p.Lys536Gln 7914197:97:185
status: NEW
Login to comment

161 Autoradiogram of 75-pg gel-separatedmembraneproteins of wild-type (A),K536Q (B),and K536R MDRls CHO K1 cells (C) that had been photolabeled with["'Iliodomycin in thepresence of (from left to right in eachpanel) 0,15,and 300 nM vinblastine.
X
ABCC7 p.Lys536Gln 7914197:161:70
status: NEW
Login to comment

190 The phenotype of multidrug resistance and collateral sensitivity was retained in the K536Q and K536R MDRl variants.
X
ABCC7 p.Lys536Gln 7914197:190:85
status: NEW
Login to comment

192 K536Q P-glycoprotein was 2-5-fold less drug resistant thanwild type (which also explains the inefficacyof the K536Q substitution in the AY490 MDRl mutant), but K536R P-glycoprotein was more active than wild type in CHO K1 transfectants.
X
ABCC7 p.Lys536Gln 7914197:192:0
status: NEW
X
ABCC7 p.Lys536Gln 7914197:192:110
status: NEW
Login to comment